Roche Holding AG shows a mixed range of outcomes concerning their stocks. Roche is increasing its
dividend to CHF9.70 and aims to pay a larger dividend than last year.
Analysts have raised Roche's target stock price, and UBS has upgraded the rating to buy. Roche is moving strong in the fat loss market, forming a strategic collaboration with
Zealand Pharma for
obesity treatment in a $5.3 billion deal and showing promise with the early-stage trial results of their obesity drug. Roche completed an acquisition of
U.S. biopharma company Poseida with 66% share tender success. Conversely, Roche also battles headwinds, notably its stock declines due to side effect concerns from its obesity drug – vomiting, causing a slump in stocks. Roche also abandoned its
global diversity targets due to concerns over U.S. executive orders, which stirred controversy.
Roche Stocks News Analytics from Thu, 16 May 2024 07:00:00 GMT to Sat, 22 Mar 2025 08:42:08 GMT -
Rating 0
- Innovation 4
- Information 6
- Rumor -5
